Compare AbbVie Inc (ABBV) vs ON Holding AG (ONON) Price & Performance

AbbVie (ABBV) trades at $247.91, up 0.76% on the day, with strong technical momentum as the stock approaches resistance near $249. The company demonstrates solid fundamentals with Q2 2026 EPS beating expectations at $3.65 versus $3.61, driven by robust immunology portfolio growth from Skyrizi and Rinvoq offsetting Humira declines. Revenue reached $61.16B in 2025 with a 71.48% gross margin, though net income margin compressed to 9.8%. Recent positive Phase 2 ovarian cancer data and institutional accumulation signal confidence in the pipeline.

Outlook remains positive with analyst consensus target of $281.33 (13.5% upside) and 71% buy ratings, though elevated P/E of 70.05 reflects growth expectations. Key risks include patent cliffs in the 2030s, competitive pressures, and regulatory uncertainties from drug pricing lawsuits. The dividend aristocrat offers income stability with recent $1.73 payout, but investors should monitor execution of oncology pipeline and debt levels at 50.4% of assets.

ONON trades at $37.55, up 0.56% with bullish technical signals supported by moving averages. The company demonstrates strong fundamental performance with Q1 2026 EPS beating expectations at $0.47 vs. $0.34 expected, maintaining a streak of earnings surprises. Revenue growth to $3.01B in 2025 and expanding net margins to 8.02% reflect operational strength amid positive analyst sentiment.

The outlook remains positive with 77% analyst buy ratings and $52.57 consensus price target suggesting 40% upside potential. Key risks include premium valuation metrics (P/E 41.8, P/S 6.5) and tariff exposure, but strong DTC growth and margin expansion support the bullish case for growth investors seeking athletic footwear exposure.